26 results about "Aging-associated diseases" patented technology

The invention relates to the technical field of biology, and discloses a method and equipment for dynamically detecting damage caused by ROS, and the method comprises the following steps: A, mixing ROS with a DNA skeleton nanostructure, and carrying out oxidative damage reaction; step B, within a period of time after the oxidative damage reaction occurs, sampling the morphological characteristics of the reaction product at multiple time points, and observing the change process of the morphological characteristics; c, according to the change process, the degree of damage caused by ROS to the DNA skeleton nanostructure is judged, and equipment capable of achieving the method comprises an ROS generation module, the DNA skeleton nanostructure, an oxidative damage reaction module and a data analysis module. The method can solve the problem that two types of ROS are difficult to visually distinguish in the prior art, can be used as a general system for evaluating the ROS regulation effect and performance of a nano material, and provides a new insight and method for deeply understanding the effect of ROS in biology and medicine, especially prevention and treatment of cancer and senescence related diseases.

The technology relates in part to compositions containing a cell penetrating peptide that can be used to selectively reduce a senescent cell population. The technology also relates to methods of treatment of ageing and ageing-associated diseases using a cell penetrating peptide to selectively reduce a senescent cell population.

The application discloses application of a novel peptide UHP in preparation of a medicine for treating and / or preventing delayed aging, and belongs to the technical field of biological medicines.The novel peptide UHP is composed of 37 L-type amino acids including a transmembrane peptide HIV-TAT.It is proved by cell experiments that the novel peptide UHP significantly improves the aging phenotype of a HGPS cell model simulated by overexpression of progerin and a replicative senescent human normal fibroblast cell, reduces the SA-beta-gal positive cell proportion and the expression of SASP factors, and increases the expression levels of cell proliferation markers Ki67, Lamin B1 and Cyclin A2.It is proved by animal experiments that the novel peptide UHP can improve the progeria phenotype, body weight and exercise capacity of a progeria mouse, relieve fibrosis in multiple tissues, improve the skin aging phenotype, and prolong the survival period of the progeria mouse, thereby providing a new medicine selection for clinical treatment of aging-related diseases.

The invention discloses an application of N4-acetylcytidine (ac4C) in preparation of a medicine for delaying senescence and prolonging life. The method is realized by reducing the overall ac4C modification level of RNA (including rRNA, tRNA, mRNA, ncRNA and the like) in a living body, and specifically can be realized by inhibiting the expression of a key catalytic adapter protein THUMPD1 or using an inhibitor targeting THUMPD1 / ac4C. The invention also provides an application of a reagent for detecting the aging degree or diagnosing aging-related diseases, such as Alzheimer's disease, mitochondrial diseases, tumors and the like, in preparation of a detection kit based on the ac4C modification level of a specific target RNA molecule, and provides a brand new target spot and strategy for aging intervention and accompanying disease diagnosis and treatment.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

The present invention relates to a composition for preventing, alleviating, or treating neuronal aging-related diseases or disorders, the composition comprising extracellular vesicles derived from three-dimensional spheroid-type cell aggregates. The extracellular vesicles according to the present invention can reduce the expression of aging-related proteins and induce reactivation of aged neural stem cells, and thus can be used to treat various neuronal aging-related diseases or disorders by preventing, alleviating, or treating the aging of neurons.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

The application discloses an engineered exosome targeting human urokinase-type plasminogen activator receptor uPAR and a preparation method and application thereof. Firstly, a high-affinity anti-human uPAR single-domain antibody VHH is prepared; then, a human umbilical cord mesenchymal stem cell engineering cell line expressing a VHH-PTGFRN fusion protein is constructed, and the engineered exosome is prepared and purified by combining three-dimensional hypoxic culture, chemical induction and size-exclusion chromatography technology. The engineered exosome comprises four comparative samples, wherein the core sample Exo^(VHH / miR) can simultaneously display the anti-uPAR VHH on the membrane surface to realize targeted delivery and enrich miR-193b-3p in the chamber to realize gene silencing, and the synergistic effect of the two can efficiently remove the uPAR high-expression senescent cells and inhibit the senescence-associated secretory phenotype SASP. The engineered exosome has the advantages of standardized preparation process, high yield and high purity, strong targeting, excellent curative effect and good safety, and can be used for preparing a treatment preparation for anti-aging and aging-related diseases, and has important clinical application value.

This invention provides a method for preparing and applying a nanosystem for regulating the osteogenic microenvironment. The nanosystem comprises catalase, lactate oxidase, and a strontium-containing mineralized nanolayer. Experiments demonstrate that this nanosystem can effectively treat bone aging-related diseases, and that catalase and lactate oxidase have a synergistic effect. This invention provides a novel treatment strategy for bone aging-related diseases and has broad prospects for clinical translation.

A method of treating an aging-related disorder includes identifying a subject having an aging-related disorder and administering to the subject a therapeutically effective amount of a desialylated O-glycosylated glycoprotein, wherein the therapeutically effective amount is between 0.1 mg / kg and 500 mg / kg with respect to a body weight of the subject. Also disclosed are methods for producing the desialylated O-glycosylated glycoprotein using a clonal cell lacking sialyltransferase activity.

The invention relates to the field of biological detection, in particular to a multi-omics combined screening cell senescence marker detection method and application thereof. According to the method, data of genomics, transcriptomics, proteomics and metabonomics are combined, and multi-dimensional data in the cell senescence process are subjected to high-throughput screening and integration by means of whole genome sequencing, RNA-Seq, a liquid chromatography-mass spectrometry technology and a gas chromatography-mass spectrometry technology. And adopting machine learning algorithms such as random forest, a support vector machine and deep learning to screen out key markers related to aging. The markers comprise genes, proteins and metabolites, and have relatively high sensitivity and specificity. Verification of different aging models proves that the screened markers change significantly in the aging process and can effectively reflect the biological characteristics of cell aging. The method provides new technical support and theoretical basis for research of an aging mechanism, early diagnosis of aging-related diseases and anti-aging treatment.

The invention belongs to the technical field of physiological detection, and provides a physiological age detection method and device based on the VOC concentration of gas exhaled by a human body, and the device comprises an exhaled gas sampler 6 and a data analysis processing device 7; the exhaled gas sampler 6 is used for collecting exhaled gas of a human body; the data analysis processing device 7 comprises a VOC detection sensor 9, a data processing module and a result output module; the VOC detection sensor 9 is used for detecting various target VOC concentrations in gas exhaled by a human body, and the data processing module is used for calculating the physiological age according to the various target VOC concentrations; the result output module is used for outputting the physiological age; through a non-invasive sample collection mode, the method is suitable for all people with physiological age detection requirements, covers the whole age group, reduces the sampling and detection cost, shortens the detection period, improves the prediction accuracy and stability, and finally realizes large-scale popularization and application of physiological age prediction. And support is provided for health management of the whole people and early warning of senescence-related diseases.

The present invention relates to a method for identifying the aging degree of a subject or a tissue or organ thereof, and for evaluating the effect of anti-aging interventions. Specifically, provided is a method for identifying the aging degree of a subject or a cell, tissue or organ thereof, or for evaluating the biological age of the subject or diagnosing premature aging disorders, which method predicts the aging status of a tissue or organ of a subject on the basis of the levels of DNA methylation, gene transcripts, proteins or metabolites. The present invention further relates to the use of metformin in the preparation of a drug for treating, preventing or delaying aging-related diseases or conditions in primates, preferably humans.

The invention provides application of a targeted histone H4K77 acetylation modified substance in preparation of a medicine for delaying immune aging, a modified stem progenitor cell and application of the modified stem progenitor cell, and belongs to the technical field of medicine. The target histone H4K77 acetylation modification or acetylation-like modification substance is a substance for increasing the histone H4K77 acetylation modification level or acetylation-like modification level in hematopoietic stem cells and / or hematopoietic progenitor cells. It is found for the first time that by increasing histone H4K77 acetylation modification or acetylation-like modification, immune senescence and systemic senescence caused by immune senescence can be effectively delayed, and immune senescence and systemic senescence related diseases caused by immune senescence can be treated. The invention provides a new choice for clinically delaying immune senescence and systemic senescence caused by immune senescence and treating immune senescence and systemic senescence related diseases caused by immune senescence, and has a wide application prospect.

The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hematological disorder, liver disease, or hepatic fibrosis, comprising administering to a subject diagnosed with said telomere biology disorder a therapeutically effective amount of said compounds.

The present invention relates to the field of biomedicine. Disclosed are a molecule for targeting senescent cells to stimulate endogenous immunity and use thereof. The drug provided by the present invention can mediate the interaction between senescent cells and immune cells, enhance the endogenous immune function, and achieve the goals of effectively clearing senescent cells and ameliorating aging-related diseases. A class of functional molecules targeting immune sensitization of senescent cells is provided. One end of the molecule targets membrane molecules of senescent cells, and labels the surface of senescent cells with glutamic acid, so as to mediate "coupling" between endogenous immune cells and senescent cells, thereby promoting the adhesion and clearance of senescent cells by immune cells. The molecule can regulate the immune microenvironment of aging tissues, and effectively reduce the number of senescence-associated β-galactosidase-positive senescent cells, while reversing fibrosis and improving the natural aging phenotype.

The invention relates to a multiple shRNA combination and application thereof, and belongs to the technical field of biology. The combination comprises a first transcription unit, a second transcription unit and a third transcription unit which are located on the same expression vector and respectively silence three different target genes in a targeted manner. Each transcription unit comprises an RNA (Ribonucleic Acid) polymerase III promoter, an shRNA (Short Hairpin Ribonucleic Acid) coding sequence and a transcription termination signal; and promoters for driving the three transcription units are different from one another and are selected from any three of hU6, mU6, hH1, h7SK, mini-hU6, H1-7SK and hH1-core. According to the technology, simultaneous efficient, stable and lasting silencing of three target genes is realized by avoiding homologous recombination, nucleic acid constructs and expression vectors can be constructed and introduced into immune cells, the functions of the immune cells are effectively enhanced, and the method has application prospects in the fields of treatment of tumors, autoimmune diseases, senescence-related diseases and the like.

The application provides application of animal Bifidobacterium lactis BGI-L99 in prevention and treatment of hormone imbalance and aging related diseases, and belongs to the technical field of biotechnology. The aforementioned animal Bifidobacterium lactis BGI-L99 is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on March 31, 2026, and the preservation number is GDMCC No. 68017. Products prepared from the animal Bifidobacterium lactis BGI-L99 in the examples of the application can effectively prevent and treat sex hormone imbalance related diseases and delay aging related degenerative diseases, including relieving polycystic ovary syndrome and osteoporosis, specifically including improving ovarian function, endocrine disorder, depression, metabolic disorder, inflammatory reaction, abnormal intestinal metabolic product, bone microstructure degradation, imbalance between bone formation and bone resorption and the like.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition with a synergistic anti-aging effect as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition specifically consists of dihydroquercetin and fisetin. According to the invention, two core anti-aging mechanisms of oxidation resistance and senescence cell removal are organically integrated for the first time, and multi-target collaborative intervention on the senescence process is realized. Compared with a single component, the composition not only can effectively repair oxidative damage, but also can selectively remove accumulated senescent cells, plays a role from the source and the result at the same time, overcomes the defects that a traditional single strategy is single in action path and limited in effect, and has a good application prospect. A more comprehensive and efficient new scheme is provided for delaying senescence and preventing and treating senescence-related diseases.

This invention discloses a small molecule composition for restoring the immunomodulatory function of senescent mesenchymal stem cells (MSCs) and its applications. It belongs to the field of biomedical technology. The small molecule composition comprises resveratrol, quercetin, ginsenoside Rg1, and N-(4-phenylbutyl)acetamide in a weight ratio of 1:2:2:1. Experiments show that this composition significantly reduces the SA-β-gal positivity rate of senescent MSCs (from 76.3% to 11.2%), inhibits T cell proliferation by 89.7%, and reduces TNF-α and IFN-γ by 76.8% and 77.5%, respectively, with significantly better effects than the individual use of each component or any combination of the three drugs. Pathway inhibitor recovery experiments confirm that its synergistic effect depends on the simultaneous activation of multiple pathways. This composition can be used to prepare drugs or cell culture additives for restoring the immunomodulatory function of senescent MSCs, providing a new approach for stem cell therapy of age-related diseases.

The disclosure provides an anti-aging method. The method includes applying JWA gene to produce or screen anti-aging products, or products associated with treatment of aging-related diseases, or anti-oxidation products, or products for maintaining homeostasis, or products associated with diagnosis of aging or aging-related diseases, or agonists of the JWA gene.

A pharmaceutical composition and method are provided which may be used for the treatment and prevention of various infections, diseases, and conditions. Preferably, the composition and method may be used for preventing and treating of aging and aging associated disease and its use (or method). Preferably, the composition and method may be used for treating and prophylaxis of microbial infectious diseases and associated inflammatory disorders and its use (or method). The pharmaceutical composition according to the invention includes a therapeutic agent X or a pharmaceutically acceptable salt thereof; a therapeutic agent Y or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, in which the therapeutic agent X is a non-steroidal anti-inflammatory drug and the therapeutic agent Y is a fatty acid oxidation inhibitor.

Disclosed are a single-domain antibody specifically binding to CD16A, a heavy-chain antibody comprising the single-domain antibody, a bispecific antibody comprising the single-domain antibody, an immunoconjugate comprising the single-domain antibody, and a conjugate comprising the single-domain antibody. And a pharmaceutical composition and its use for the treatment, prevention or diagnosis of cancer, acute or chronic infection or aging-related diseases.

This invention discloses a method for rejuvenating senescent cells based on osmotic pressure induction. Senescent cells typically exhibit cell volume expansion. This method constructs a hypertonic environment by introducing a biocompatible polymeric solute (such as 2% or 0.5% PEG 300), applying controlled hypertonic pressure to senescent cells to induce cytoplasmic dehydration and counteract volume expansion. Experiments have demonstrated that long-term hypertonic compression intervention (such as 7 days of 0.5% PEG treatment) can effectively reset the mechanical state of senescent cells. After removing the pressure and restoring isotonic culture, some senescent cells can regain their proliferative capacity, as evidenced by negative SA-β-gal staining, strong positivity for Ki67 and EdU proliferation markers, and long-term stable passage. This invention provides a non-genetic, physical means to achieve cell rejuvenation, offering a new pathway for the intervention of age-related diseases.

The application provides application of tRF-16 in preparation of products for resisting liver aging and treating liver aging related diseases, and belongs to the technical field of biological medicine. It is found in the application that a new target point for restoring and / or delaying D-galactose induced liver aging and treating D-galactose induced liver aging related diseases is discovered, and experiments prove that by regulating tRF-16 in the body, the expression of SOD2 can be further regulated, the vicious cycle of "increased active oxygen-DNA damage-liver aging" can be blocked, the oxidation-reduction balance is restored and oxidative stress is reduced, and the expression of key aging markers such as P16, P21 and P53 is lowered, so that the occurrence of liver aging is delayed or inhibited, and the healthy life span of cells and tissues is prolonged.

Provided are chimeric molecules, compositions, and applications thereof that specifically bind to natriuretic peptide receptor C (NPR-C). The disclosed chimera comprises an NPR-C binding domain and a target-binding domain. Through NPR-C-mediated endocytosis, the chimera enables the intracellular degradation of the target by lysosomal enzymes. The chimeric molecules can rapidly, conveniently, and precisely degrade target proteins. Their modular design permits broad applicability to proteins such as secreted proteins and membrane-associated proteins. These chimeric molecules exhibit high bioavailability and low immunogenicity, thus being broadly applicable for the treatment of diseases including cancer, neurodegenerative diseases, psychiatric disease, central nervous system diseases, inflammatory diseases, autoimmune diseases, metabolic syndrome, tissue fibrotic disease, cardiovascular diseases, respiratory diseases, digestive diseases, renal diseases, hematologic diseases, infectious diseases, rare diseases and aging-related disease.